Collplant Biotechnologies Ltd (CLGN) FinancialsCLGNCollplant Biotechnologies Ltd

Collplant Biotechnologies Ltd (CLGN) generates its revenue primarily from Revenues from the sales of goods, which accounts for 100.0% of total sales, equivalent to $179.00K. Understanding this concentration is critical for investors evaluating how CLGN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Collplant Biotechnologies Ltd maintains a gross margin of -332.88%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4267.12%, while the net margin is -4242.47%. These profitability ratios, combined with a Return on Equity (ROE) of -151.99%, provide a clear picture of how effectively CLGN converts its operational activities into shareholder value.

In the context of the broader market, CLGN competes directly with industry leaders such as BMRA and TRIB. With a market capitalization of $5.16M, it holds a significant position in the sector. When comparing efficiency, CLGN's gross margin of -332.88% stands against BMRA's -4.46% and TRIB's 35.21%. Such benchmarking helps identify whether Collplant Biotechnologies Ltd is trading at a premium or discount relative to its financial performance.

Collplant's financial performance shows significant volatility. In Q1 2026, the company reported a revenue of only $0.07 million, which is far below market expectations. The gross margin fluctuated dramatically, with a gross profit of 90.85% in Q1 2025, but negative margins in subsequent quarters. The net income has consistently been negative, with a net income of -$3.1 million in Q1 2026.